-+ 0.00%
-+ 0.00%
-+ 0.00%

Hanyu Pharmaceutical (300199.SZ): HY3003 injection was accepted by the US FDA for clinical trials

Zhitongcaijing·10/08/2026 08:41:05
Listen to the news

Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received a notice from the US Food and Drug Administration (FDA) to accept the clinical trial application for HY3003 injection.

HY3003 is a GLP-1R/GIPR/GCGR three-target receptor agonist selected using AI polypeptide chip technology. It is intended for use in indications such as weight loss, type 2 diabetes, and metabolism-related fatty hepatitis. It is a major innovative drug type in the company's layout in the field of metabolic diseases. The HY3003 project uses a multi-dosage parallel development strategy. The development direction includes HY3003 injection (weekly formulation), HY3003 extended-release injection (monthly formulation), and HY3003 tablets (once-daily oral formulation).